| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Stanford Stroke Center (Drs. Hsia, Hamilton, and Tong), Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, and Department of Neurology (Dr. Sachdev, J. Tomlinson), Good Samaritan Hospital, San Jose, CA.
Address correspondence and reprint requests to Dr. D.C. Tong, Stanford Stroke Center, 701 Welch Rd., Suite B325, Palo Alto, CA 94304-0117; e-mail: dct{at}Stanford.edu
Background: The National Institute of Neurological Disorders and Stroke (NINDS) trial reported that stroke subtype (e.g., large-artery atherothrombosis, cardioembolism, and lacunae) does not affect response to IV thrombolytic treatment. However, these conclusions were based upon stroke subtypes determined prior to extensive diagnostic evaluation. Because such initial diagnoses are frequently inaccurate, the efficacy of IV recombinant tissue plasminogen activator (rt-PA) based upon verified specific stroke subtypes remains uncertain.
Methods: The records of consecutive acute stroke patients treated with IV rt-PA at two regional stroke centers were retrospectively reviewed. The final stroke subtype after complete diagnostic evaluation was determined. The relationship between final stroke subtype and response to thrombolytic therapy was then investigated and compared with the results reported in the NINDS trial.
Results: Ninety consecutive patients were studied. After adjusting for baseline NIH Stroke Scale scores, no significant difference in final outcome based on confirmed stroke mechanism was identified.
Conclusions: These data are consistent with those of the NINDS trial that reported that the efficacy of IV thrombolysis within the 3-hour time window is similar between different stroke subtypes. Based upon these data, allocating treatment of stroke patients with IV rt-PA based upon presumed stroke mechanism may be unnecessary. Such testing may result in time delays that could compromise the efficacy of treatment.
This article has been cited by other articles:
|
|
 |
|
  S. W. Youn, J. H. Kim, Y.-C. Weon, S. H. Kim, M.-K. Han, and H.-J. Bae Perfusion CT of the Brain Using 40-mm-Wide Detector and Toggling Table Technique for Initial Imaging of Acute Stroke Am. J. Roentgenol., September 1, 2008; 191(3): W120 - W126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Norrving Lacunar infarcts: no black holes in the brain are benign Practical Neurology, August 1, 2008; 8(4): 222 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ciccone, L. Valvassori, R. Gasparotti, F. Scomazzoni, E. Ballabio, and R. Sterzi Debunking 7 Myths That Hamper the Realization of Randomized Controlled Trials on Intra-Arterial Thrombolysis for Acute Ischemic Stroke Stroke, July 1, 2007; 38(7): 2191 - 2195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wilczak, J. W. Elting, D. Chesik, I. P. Kema, and J. De Keyser Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1 Stroke, September 1, 2006; 37(9): 2368 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamaguchi, E. Mori, K. Minematsu, J. Nakagawara, K. Hashi, I. Saito, Y. Shinohara, and for the Japan Alteplase Clinical Trial (J-ACT) Gro Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) * Supplemental Appendix 2 Stroke, July 1, 2006; 37(7): 1810 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Adams, R. Adams, G. Del Zoppo, and L. B. Goldstein Guidelines for the Early Management of Patients With Ischemic Stroke: 2005 Guidelines Update A Scientific Statement From the Stroke Council of the American Heart Association/American Stroke Association Stroke, April 1, 2005; 36(4): 916 - 923. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
